Domain Therapeutics, a French and Canadian privately-held biopharmaceutical company, is using transmembrane and G Protein-Coupled Receptor (GPCR) targeting for the discovery and development of innovative therapeutics for the treatment of Central Nervous System (CNS) diseases and cancer.
Using its commercially proven candidate discovery engine (Takeda, Merck Serono and ONO Pharmaceutical), Domain has created a pipeline of high-value projects and partnerships. Validating this approach, two projects discovered by Domain Therapeutics technologies are planned to enter clinical Phase I in early and late 2016.
Domain Therapeutics applies a multi-string corporate strategy to grow its business through:
Domain will present at the BIO Europe Congress on November 7-9, 2016 in Cologne, Germany (USA)
Domain Therapeutics signed an exclusive license with universities of Montreal and McGill
Prexton Therapeutics completes phase 1 clinical trial with PXT002331
PeptiMimesis secures €1.2m ($1.4m) from Cap Innov’Est